AlzChem Group AG
AlzChem Group AG (ALZCF) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for AlzChem Group AG (ALZCF), featuring income statements, balance sheets, and cash flow data.
AlzChem Group AG (ALZCF) Income Statement & Financial Overview
Analyze AlzChem Group AG’s ALZCF earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $144.68M | $137.24M | $128.94M | $136.19M |
| Cost of Revenue | $52.80M | $65.04M | $44.86M | $48.19M |
| Gross Profit | $91.88M | $72.20M | $84.08M | $92.33M |
| Gross Profit Ratio | $0.64 | $0.53 | $0.65 | $0.68 |
| R&D Expenses | $0.00 | $10.83M | $0.00 | $0.00 |
| SG&A Expenses | $0.00 | $43.13M | $38.10M | $8.78M |
| Operating Expenses | $71.07M | $53.96M | $84.08M | $43.26M |
| Total Costs & Expenses | $123.87M | $119.00M | $110.46M | $115.91M |
| Interest Income | $711000.00 | $744000.00 | $450000.00 | $687000.00 |
| Interest Expense | $1.28M | $1.42M | $1.54M | $1.37M |
| Depreciation & Amortization | $6.55M | $4.10M | $6.40M | $6.45M |
| EBITDA | $28.07M | $21.62M | $25.33M | $28.01M |
| EBITDA Ratio | $0.19 | $0.16 | $0.20 | $0.21 |
| Operating Income | $20.81M | $18.24M | $49.69M | $20.29M |
| Operating Income Ratio | $0.14 | $0.13 | $0.39 | $0.15 |
| Other Income/Expenses (Net) | -$567000.00 | $2.60M | -$32.30M | -$398000.00 |
| Income Before Tax | $20.24M | $20.85M | $17.39M | $19.89M |
| Income Before Tax Ratio | $0.14 | $0.15 | $0.13 | $0.15 |
| Income Tax Expense | $5.61M | $5.68M | $4.97M | $5.46M |
| Net Income | $14.59M | $15.12M | $12.38M | $14.38M |
| Net Income Ratio | $0.10 | $0.11 | $0.10 | $0.11 |
| EPS | $1.44 | $1.49 | $1.22 | $1.41 |
| Diluted EPS | $1.44 | $1.49 | $1.22 | $1.41 |
| Weighted Avg Shares Outstanding | $10.11M | $10.15M | $10.18M | $10.18M |
| Weighted Avg Shares Outstanding (Diluted) | $10.11M | $10.15M | $10.18M | $10.18M |
The company's financials show resilient growth, with revenue advancing from $136.19M in Q2 2024 to $144.68M in Q1 2025. Gross profit remained healthy with margins at 64% in Q1 2025 compared to 68% in Q2 2024. Operating income hit $20.81M last quarter, sustaining a consistent 14% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $28.07M. Net income dropped to $14.59M, while earnings per share reached $1.44. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan